drugset / Trial / NCT00876421

Study of ONO-8539 in Patients With Overactive Bladder

NCT00876421

Phase 2 Completed 435 enrolled Ono Pharmaceutical Co., Ltd.
RandomizedParallel-groupQuadruple-blindTreatment

Summary

The objective of this study is to investigate efficacy, safety and tolerability of ONO-8539 in patients with overactive bladder.

Timeline

Start
2009-04
Primary completion
2010-04
Completion

Drugs

EvaluationDrugModalityDoseRoute
Subject ONO-8539 Small molecule
Comparator Tolterodine Small molecule 4 mg

Indications